Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout

Willburger, R. E.; Mysler, Eduardo; Derbot, J.; Jung, Tae Hoon; Thurston, Helen; Kreiss, Andreas; Litschig, Stephane; Krammer, Gerhard; Tate, Guillermo

doi:10.1093/rheumatology/kem090

Cited by 50 publications

(35 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cyclooxygenase 2 (COX-2) inhibitors are an option for patients with gastrointestinal contraindications or intolerance to NSAIDs. Several randomized controlled trials (RCTs) have been published that support the efficacy of COX-2 inhibitors like etoricoxib, lumiracoxib, and celecoxib [9][10][11]. However, there is still not much evidence to indicate efficacy of these treatments.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis

Zhang

Liu

et al. 2015

Clin Rheumatol

View full text Add to dashboard Cite

The aim is to study the efficacy and safety of etoricoxib in the treatment of acute gout, as compared with non-steroidal anti-inflammatory drugs (NSAIDs). We conducted a computerized search of electronic databases: PubMed, EMBASE, Web of Science, China Biology Medicine disc, and Cochrane Library. The search terms were as follows: gout arthritis, tophus, etoricoxib, indometacin naproxen, diclofenac, and NSAIDs. Articles were searched from 1983 until August 2014. A manual search of peer-reviewed English documents was performed by cross-checking the bibliographies of selected studies. These trials reported pain relief as the primary outcome. Tenderness, swelling, patients' global assessments of response to treatment, and investigators' global assessments of response to treatment were reported as the secondary outcomes. All adverse events were recorded for safety assessment. Six trials including 851 patients were identified. Both etoricoxib and NSAIDs had an effect on inflammation and analgesia. Compared with indometacin and diclofenac, etoricoxib had a lower incidence of adverse events. Etoricoxib 120 mg administered orally once daily has the same efficacy on acute gout as indometacin and diclofenac. Etoricoxib is tolerated better by patients than NSAIDs such as indometacin and diclofenac.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis

Zhang

Liu

et al. 2015

Clin Rheumatol

View full text Add to dashboard Cite

show abstract

“…There has been renewed interest in the treatment of gout with recent reported intervention studies of new agents, including etoricoxib,1 lumiracoxib2 in acute gout or attacks of gout and febuxostat,3 pegylated-uricase4 in chronic gout. These studies have highlighted the relative paucity of validated outcome measures with which to judge efficacy.…”

mentioning

confidence: 99%

A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout

Taylor

Schumacher

Baraf

et al. 2008

Annals of the Rheumatic Diseases

View full text Add to dashboard Cite

Consensus is that the following domains be considered mandatory for acute gout studies: pain, joint swelling, joint tenderness, patient global, physician global, functional disability; and for chronic gout studies: serum urate, gout flares, tophus regression, health-related quality of life, functional disability, pain, patient global, physician global, work disability and joint inflammation. Several additional domains were considered discretionary.

show abstract

“…[10] for the treatment of acute gout. However, analgesic and anti-inflammatory doses of other NSAIDs may be as effective.…”

Section: World Journal Of Pharmacy and Pharmaceutical Sciencesmentioning

confidence: 99%

Revisiting Gout With New Treatment Strategy: Lesinurad.

Kaur¹

2017

WJPPS

View full text Add to dashboard Cite

show abstract

Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout

Abstract: Lumiracoxib is as effective as indomethacin for treatment of acute gout and may have a better safety and tolerability profile.

Cited by 50 publications

References 22 publications

Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis

Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis

A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout

Revisiting Gout With New Treatment Strategy: Lesinurad.

Contact Info

Product

Resources

About